Program
sotiburafusp alfa
Also written as “HB0025 Injection”, “HB0025” and “HB0025 20 mg/kg plus nab-paclitaxel”.
Its studies are mostly in Endometrial Neoplasms · Carcinoma, Non-Small-Cell Lung · Kidney Neoplasms · Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huabo Biopharm | 32 open or running | phase 2since Jan 15, 2024 | Dec 15, 2020 | Jan 15, 2027phase 2 · NCT07376629 |
| Shanghai Huaota Biopharmaceutical | 22 open or running | phase 3since Jan 15, 2026 | Jan 15, 2026 | Apr 10, 2028phase 3 · NCT07383116 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2020First study: phase 1 study in NeoplasmsNew to Huabo BiopharmHuabo Biopharm · NCT04678908 · 154 enrolled · United States, China
- Jan 15, 2024Phase 2 study in Kidney NeoplasmsHuabo Biopharm · NCT06222125 · 100 planned · China
- Jan 13, 2026Phase 2 study in TNBCHuabo Biopharm · NCT07376629 · 60 planned · China
- Jan 15, 2026Shanghai Huaota Biopharmaceutical’s first study: phase 3 study in Non Squamous Non-small Cell Lung CancerNew to Shanghai Huaota BiopharmaceuticalShanghai Huaota Biopharmaceutical · NCT07383116 · 500 planned · China
- Oct 20, 2026Phase 3 study in First-line pMMR Endometrial CancerShanghai Huaota Biopharmaceutical · NCT07902999 · 333 planned · China
Ahead
- Jan 15, 2027Primary completion: phase 2 study in TNBCHuabo Biopharm · NCT07376629
- Apr 10, 2028Primary completion: phase 3 study in Non Squamous Non-small Cell Lung CancerShanghai Huaota Biopharmaceutical · NCT07383116
- Apr 23, 2029Primary completion: phase 3 study in First-line pMMR Endometrial CancerShanghai Huaota Biopharmaceutical · NCT07902999
TargetBeta
“A recombinant, humanized fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) ”NCIt, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07902999First-line pMMR Endometrial Cancer · China | 3 | Recruiting | Shanghai Huaota Biopharmaceutical | Apr 23, 2029 | 333 |
| NCT07383116Non Squamous Non-small Cell Lung Cancer · China | 3 | Not yet recruiting | Shanghai Huaota Biopharmaceutical | Apr 10, 2028 | 500 |
| NCT07376629TNBC · China | 2 | By invitation | Huabo Biopharm | Jan 15, 2027 | 60 |
| NCT06222125Kidney Neoplasms · China | 2 | Recruiting | Huabo Biopharm | Jan 30, 2025 | 100 |
| NCT04678908Neoplasms · United States, China | 1 | UNKNOWN | Huabo Biopharm | Feb 2, 2024 | 154 |
How it is read
Names in the registry
- “HB0025 Injection”, 2 entries
- “HB0025”, 2 entries
- “HB0025 20 mg/kg plus nab-paclitaxel”, 1 entry
- “HB0025 10 mg/kg plus nab-paclitaxel”, 1 entry
Conditions, from the studies’ own filings
- Endometrial Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Kidney Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.